Clinical trials
HPV Positive Oropharyngeal Squamous Cell Carcinoma clinical trials
Below are recruiting hpv positive oropharyngeal squamous cell carcinoma clinical trials, each written for real people, not researchers. We’re tracking 78 recruiting studies, each written for real people, not researchers, below.
Recruiting studies
- NCT04220749RecruitingPhase 2
Radiation vs mouth surgery for HPV-negative throat cancer
This Phase 2 trial compares two standard cancer treatments—radiation or surgery through the mouth—for HPV-negative oropharyngeal throat cancer. It aims to find out which approach works better while keeping side effects and quality of life acceptable.
London, OntarioAges 18 years+ - NCT04681469RecruitingPhase 2
Niraparib plus immunotherapy for HPV-negative head and neck cancer
This Phase 2 study tests a cancer “induction then maintenance” plan using a PARP inhibitor (niraparib) along with immunotherapy (TSR-042) in people with HPV-negative head and neck squamous cell cancer. If it works, it may improve control of the cancer after surgery by boosting the immune system and targeting cancer cells’ DNA repair.
BresciaAges 18 years+ - NCT04444869RecruitingPhase 2
Lower-dose radiation with chemotherapy for low-risk HPV throat cancer
This trial tests whether a less intense (lower-dose) radiation plan, combined with chemotherapy, can control HPV-positive oropharyngeal (throat) cancer with fewer side effects. It targets people considered “low-risk” based on tumor size and lymph node involvement.
Columbia, MissouriAges 18 years+ - NCT04688528Recruiting
Radiation planning to spare the opposite neck in head cancer
This trial tests a safer radiation plan that may reduce dose to the opposite (other) side of the neck while still treating the cancer spread risk. It uses special mapping to guide treatment and looks at patients whose cancer is already in an involved lymph node on one side.
Genk, LimburgAges 18 years+ - NCT07718620Recruiting
HPV-related throat cancer radiation trial
This trial tests whether radiation or chemoradiation works well for HPV-positive throat cancer. It may be an option if you have this type of cancer and are getting or have already had surgery.
Brno, Czech RepublicAges 18 years+ - NCT07686575Recruiting
Ivonescimab with chemo for advanced mouth or throat cancer
This trial tests a new drug, ivonescimab, combined with chemotherapy for people with advanced mouth or throat cancer that can be removed with surgery. The goal is to see if the combination helps shrink tumors before surgery.
Guangzhou, GuangdongAges 18–80 - NCT06601335RecruitingPhase 3
New immunotherapy combo for head and neck cancer
This trial tests a new combination of two immunotherapy drugs (AK112 and AK117) versus the standard immunotherapy pembrolizumab for people with advanced head and neck cancer that hasn't been treated before.
Wuhan, HubeiAges 18–75 - NCT07565740RecruitingPhase 1
Vaccine plus immunotherapy for newly diagnosed HPV-positive throat cancer
This trial tests a new nasal vaccine combined with an immunotherapy drug (tislelizumab) given before surgery for people with HPV-positive oropharyngeal cancer. The goal is to help the immune system fight the cancer and potentially improve outcomes after surgery.
Chengdu, SichuanAges 18 years+ - NCT07513389RecruitingPhase 2
HPV throat cancer trial skipping radiation with blood tests
This study tests whether patients with a specific type of HPV-positive throat cancer can safely skip radiation after surgery by using blood tests to monitor for cancer recurrence. The goal is to reduce side effects while keeping patients cancer-free.
Charleston, South CarolinaAges 18 years+ - NCT07497607RecruitingPhase 2
Lower radiation dose for HPV-positive throat cancer
This trial tests a lower dose of radiation to certain neck areas for people with HPV-related oropharyngeal cancer. The goal is to see if reducing radiation can cause fewer side effects while still curing the cancer.
Cincinnati, OhioAges 18 years+ - NCT07485296RecruitingPhase 2
Postbiotics with pembrolizumab for advanced head and neck cancer
This trial tests whether adding postbiotics (beneficial bacteria byproducts) to the standard immunotherapy drug pembrolizumab can improve your immune system's response against advanced or metastatic head and neck squamous cell carcinoma.
Rozzano, MilanoAges 18 years+ - NCT07465276RecruitingPhase 2
Two immunotherapies before surgery for head and neck cancer
This trial tests a new combination of two immunotherapy drugs (ficerafusp alfa and pembrolizumab) given before surgery for advanced head and neck cancer that can be removed. The goal is to see if this approach can shrink the tumor and improve outcomes.
Boston, MassachusettsAges 18 years+ - NCT07457281RecruitingPhase 1
A new drug combo for head and neck cancer before surgery
This trial tests two drugs, GV20-0251 and Sintilimab, given before surgery for head and neck cancer. The goal is to see if this combination can shrink tumors and make surgery more effective.
ChengduAges 18–70 - NCT07455032RecruitingPhase 1
Neoadjuvant therapy combo for head and neck cancer
This trial tests a combination of two drugs (CADI-05 and pembrolizumab) before surgery for people with a certain type of head and neck cancer that hasn't spread. The goal is to see if this treatment can help shrink the tumor before it is removed.
Philadelphia, PennsylvaniaAges 18 years+ - NCT07445048RecruitingPhase 3
Radiation, targeted therapy, and immunotherapy for high-risk head and neck cancer
This trial tests if adding a targeted drug (nimotuzumab) and an immunotherapy (benmelstobart) after surgery and radiation can help prevent cancer from returning in patients with high-risk head and neck cancer who cannot take cisplatin chemotherapy.
ShanghaiAges 18 years+ - NCT07441681RecruitingPhase 3
Comparing radiation plus targeted therapy vs standard chemo for head and neck cancer
This trial compares two treatments for advanced head and neck cancer in patients who cannot take the drug cisplatin. One group gets radiation plus a targeted drug called cetuximab, the other gets radiation plus standard chemotherapy. The goal is to see which approach works better and is safer for people who are not candidates for cisplatin.
Beverly Hills, CaliforniaAges 18 years+ - NCT07408063RecruitingPhase 2
Study of new drug for advanced head and neck cancer
This trial tests a new drug (GSK5764227) for head and neck cancer that has spread or come back. It looks at your tumor's biomarkers to understand why some people respond to treatment. You may need to have had certain prior treatments depending on which group you join.
Toronto, OntarioAges 18 years+ - NCT07209189RecruitingPhase 2
Chemo and immunotherapy before surgery for head and neck cancer
This trial tests a combination of chemotherapy and an immunotherapy drug called Toripalimab before surgery for certain head and neck cancers. The goal is to see if this approach can reduce the extent of treatment needed while still being effective.
Baltimore, MarylandAges 18 years+ - NCT07195734RecruitingPhase 2
Adding chemo or immunotherapy before surgery for advanced head and neck cancer
This trial tests whether giving chemotherapy or chemotherapy plus immunotherapy before surgery can improve outcomes for people with advanced head and neck cancer that has come back or not gone away after prior treatment.
Tucson, ArizonaAges 18 years+ - NCT07172256RecruitingPhase 2
CUE-101 plus pembrolizumab for HPV+ throat cancer
This trial tests a new drug called CUE-101 combined with a standard immunotherapy (pembrolizumab) for people with HPV-16 positive head and neck cancer that cannot be removed with surgery. The goal is to see if this combination can shrink or control the cancer.
New Haven, ConnecticutAges 18 years+ - NCT07156227RecruitingPhase 1
Testing camonsertib with radiation for returning head and neck cancer
This study tests whether adding the drug camonsertib to radiation therapy can help people whose head and neck cancer has come back in a spot that was already treated with radiation. Camonsertib is an experimental drug that may help radiation work better.
Duarte, CaliforniaAges 18 years+ - NCT07063212RecruitingPhase 2
Sacituzumab govitecan plus cetuximab for head and neck cancer
This trial tests a combination of two drugs—sacituzumab govitecan and cetuximab—for people with advanced head and neck cancer that has gotten worse after immunotherapy. The goal is to see if this new treatment can shrink or slow the cancer.
Basking Ridge, New JerseyAges 18 years+ - NCT07044635RecruitingPhase 2
Shorter radiation course after robotic throat surgery
This study tests whether a shorter course of radiation therapy after robotic surgery for HPV-related throat cancer is as effective as the usual longer course. It aims to reduce side effects while maintaining good outcomes.
Salt Lake City, UtahAges 18 years+ - NCT06997094RecruitingPhase 1
Decitabine plus standard therapy for HPV-negative head and neck cancer
This trial tests whether adding the drug decitabine to standard treatment (surgery and possibly radiation) can help people with a type of head and neck cancer not caused by HPV. You would receive decitabine before surgery, and then continue with standard care after.
Jacksonville, FloridaAges 18 years+
Hear when a new HPV Positive Oropharyngeal Squamous Cell Carcinoma trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.
HPV Positive Oropharyngeal Squamous Cell Carcinoma trials by city
Studies with a site in or near these metro areas.
HPV Positive Oropharyngeal Squamous Cell Carcinoma trials by state
Studies with a site anywhere in these states.
Common questions
- Are there clinical trials for hpv positive oropharyngeal squamous cell carcinoma?
- Yes. Clin2 currently lists 78 recruiting hpv positive oropharyngeal squamous cell carcinoma studies from the U.S. registry, each rewritten for real people, not researchers, so you can see what it’s testing and who it’s for.
- How do I know if I qualify for a hpv positive oropharyngeal squamous cell carcinoma trial?
- Each study lists its eligibility criteria — rules about age, diagnosis, and prior treatments. On every Clin2 trial page we explain these in words written for real people and offer a short, optional pre-screen for a fit read. The study team makes the final decision.
- Does it cost anything to join a hpv positive oropharyngeal squamous cell carcinoma trial?
- Using Clin2 is always free. Many trials cover the cost of the study treatment and related visits; some reimburse travel. The study team explains exactly what’s covered before you decide.
Related conditions
- Oropharyngeal Squamous Cell Carcinoma
- HPV-Related Squamous Cell Carcinoma
- Recurrent Oropharyngeal Squamous Cell Carcinoma
- HPV-Related Anal Squamous Cell Carcinoma
- Metastatic Oropharyngeal Squamous Cell Carcinoma
- Oropharyngeal Squamous Cell Carcinoma (SCC)
- HPV-Negative Squamous Cell Carcinoma
- HPV-Related Penile Squamous Cell Carcinoma
Clin2 helps you find and understand clinical trials and does not provide medical advice. Study data comes from ClinicalTrials.gov. Talk with your doctor about whether a specific trial is right for you.